Detailed description page of ThPDB2
| This page displays user query in tabular form. |
Th1254 details |
| Primary information | |
|---|---|
| ID | 11718 |
| Therapeutic ID | Th1254 |
| Protein Name | Capromab pendetide |
| Sequence | NA |
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting point | 61 °C (FAB fragment), 71 °C (whole mAb) |
| Half-life | NA |
| Description | Capromab is a Murine IgG1 monoclonal 7E11-C5.3 antibody that recognizes prostate specific membrane antigen (PSMA – also known as glutamate carboxypeptidase 2) from prostate cancer cells and normal prostate tissue. When linked to pendetide, capromab is used as a chelating agent for the radionuclide [Indium In-111] during imaging to evaluate the extent of prostate cancer. |
| Indication/Disease | For diagnosis of prostate cancer and detection of intra-pelvic metastases. |
| Pharmacodynamics | Binds to the prostate-specific membrane antigen, which is a cell surface protein generally overexpressed in prostate tissues and prostate cancers. The radioactive Indium 111, which is covalently attached to the antibody, allows radiodiagnostic detection of PSMA expressing cells and tumors. |
| Mechanism of Action | Binds selectively to cell-surface prostate-specific membrane antigen (PSMA) expressed on prostate tissues and tumors. |
| Toxicity | NA |
| Metabolism | Most likely removed by opsonization via the reticuloendothelial system or by human antimurine antibody production |
| Absorption | NA |
| * 4 ± 2.1 L | |
| Clearance | * 42 +/- 22 mL/hr |
| Categories | Amino Acids, Peptides, and Proteins |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | Chlorotrianisene,Conjugated estrogens,Estrone,Dienestrol,Estriol,Quinestrol,Hexestrol,Tibolone,Synthetic Conjugated Estrogens, A,Synthetic Conjugated Estrogens, B,Polyestradiol phosphate,Esterified estrogens,Zeranol,Equol,Promestriene,Methallenestril,Epimestrol,Moxestrol,Estradiol acetate,Biochanin A,Formononetin,Diethylstilbestrol,Estradiol,Ethinylestradiol,Mestranol,Estrone sulfate,Estradiol benzoate,Estradiol cypionate,Estradiol valerate,Estetrol,Leuprolide,Goserelin,Gonadorelin,Nafarelin,Buserelin,Histrelin,Triptorelin,Deslorelin,Danazol,Elagolix,Gestrinone,Flutamide,Nilutamide,Bicalutamide,Enzalutamide,Apalutamide,Darolutamide,Cyproterone acetate,Chlormadinone,Relugolix,Chlormadinone acetate,Cetuximab,Human immunoglobulin G,Omalizumab,Adalimumab,Abciximab,Gemtuzumab ozogamicin,Indium In-111 satumomab pendetide,Infliximab,Trastuzumab,Rituximab,Basiliximab,Muromonab,Digoxin Immune Fab (Ovine),Ibritumomab tiuxetan,Tositumomab,Alemtuzumab,Efalizumab,Antithymocyte immunoglobulin (rabbit),Natalizumab,Palivizumab,Daclizumab,Bevacizumab,Technetium Tc-99m arcitumomab,Eculizumab,Panitumumab,Ranibizumab,Galiximab,Pexelizumab,Afelimomab,Epratuzumab,Bectumomab,Oregovomab,IGN311,Adecatumumab,Labetuzumab,Matuzumab,Fontolizumab,Bavituximab,CR002,Rozrolimupab,Girentuximab,Obiltoxaximab,XTL-001,NAV 1800,Briakinumab,Otelixizumab,AMG 108,Iratumumab,Enokizumab,Ramucirumab,Farletuzumab,Veltuzumab,Ustekinumab,Trastuzumab emtansine,PRO-542,TNX-901,Inotuzumab ozogamicin,RI 624,MYO-029,CT-011,Leronlimab,Glembatumumab vedotin,Olaratumab,IPH 2101,TB-402,Caplacizumab,IMC-1C11,Eldelumab,Lumiliximab,Canakinumab,Ipilimumab,Nimotuzumab,Clenoliximab,Tocilizumab,BIIB015,Sonepcizumab,Motavizumab,Elotuzumab,AVE9633,Carotuximab,XmAb 2513,Coltuximab ravtansine,Lucatumumab,Pertuzumab,Siplizumab,Apolizumab,Sibrotuzumab,Bivatuzumab,Lerdelimumab,Lexatumumab,Reslizumab,Teplizumab,Catumaxomab,Mepolizumab,Denosumab,Volociximab,Ofatumumab,Golimumab,Brentuximab vedotin,Belimumab,Raxibacumab,Obinutuzumab,Secukinumab,Vedolizumab,Nivolumab,Siltuximab,Pembrolizumab,Dulaglutide,Blinatumomab,Anthrax immune globulin human,Dinutuximab,Asfotase alfa,Idarucizumab,Alirocumab,Evolocumab,Antilymphocyte immunoglobulin (horse),Daratumumab,Necitumumab,Ixekizumab,Ravulizumab,Atezolizumab,Tetanus immune globulin, human,Eftrenonacog alfa,Human varicella-zoster immune globulin,Conatumumab,Tabalumab,Ficlatuzumab,Figitumumab,Durvalumab,Bapineuzumab,Depatuxizumab mafodotin,Onartuzumab,Solanezumab,Sarilumab,Tremelimumab,Brodalumab,Sirukumab,Lampalizumab,Guselkumab,Dalotuzumab,Emibetuzumab,Ublituximab,Ligelizumab,Seribantumab,Landogrozumab,Romosozumab,Vadastuximab talirine,Lebrikizumab,Varlilumab,Avelumab,Crenezumab,Rilotumumab,Anifrolumab,Ocrelizumab,Benralizumab,Gantenerumab,Visilizumab,Urelumab,Lorvotuzumab mertansine,Patritumab,Fulranumab,Tarextumab,Sotatercept,Gevokizumab,Duligotuzumab,Simtuzumab,Fasinumab,Dupilumab,Tralokinumab,Etrolizumab,Zalutumumab,Ganitumab,Etaracizumab,Polatuzumab vedotin,Inclacumab,Cixutumumab,Ascrinvacumab,Aducanumab,GS-5745,Vanucizumab,Labetuzumab govitecan,Tanezumab,Ensituximab,Fezakinumab,Dusigitumab,Fresolimumab,Indusatumab vedotin,Bococizumab,Mirvetuximab Soravtansine,Mogamulizumab,Plozalizumab,Inebilizumab,Mavrilimumab,Blosozumab,Bimagrumab,Dacetuzumab,Tovetumab,Lumretuzumab,Ibalizumab,Intetumumab,Carlumab,Demcizumab,Sifalimumab,Abituzumab,Ecromeximab,Naptumomab estafenatox,Crotedumab,Concizumab,Depatuxizumab,Rontalizumab,Amatuximab,Clazakizumab,Ozanezumab,Sacituzumab govitecan,Bimekizumab,Milatuzumab,Robatumumab,Rovalpituzumab tesirine,Namilumab,Racotumomab,Tregalizumab,Olokizumab,Bezlotoxumab,Edrecolomab,Nebacumab,Human cytomegalovirus immune globulin,Emicizumab,Sulesomab,Besilesomab,Tildrakizumab,Burosumab,Erenumab,Eptinezumab,Fremanezumab,Galcanezumab,Fanolesomab,Lecanemab,Lanadelumab,Cemiplimab,Emapalumab,Risankizumab,Camrelizumab,Setrusumab,Gancotamab,Anetumab ravtansine,Isatuximab,Icrucumab,Codrituzumab,Brolucizumab,Xentuzumab,Lintuzumab,Vobarilizumab,Parsatuzumab,Emactuzumab,Bevacizumab zirconium Zr-89,Refanezumab,Rozanolixizumab,Bermekimab,Pamrevlumab,Opicinumab,Trastuzumab deruxtecan,Margetuximab,Dalantercept,Pateclizumab,Gremubamab,Apomab,Tafasitamab,Ipafricept,Abrilumab,Frovocimab,Tezepelumab,Tigatuzumab,Telisotuzumab vedotin,Utomilumab,Zolbetuximab,Ponezumab,Asunercept,Suvratoxumab,Mitazalimab,Nemolizumab,Bleselumab,Gedivumab,Valanafusp alfa,Sofituzumab vedotin,Istiratumab,Pidilizumab,GMA-161,Ladiratuzumab vedotin,Tomaralimab,Vesencumab,Pinatuzumab vedotin,Lulizumab pegol,Lorukafusp alfa,Naratuximab emtansine,Zenocutuzumab,Atoltivimab,Maftivimab,Odesivimab,Belantamab mafodotin,Ansuvimab,Bamlanivimab,Hepatitis B immune globulin,Human Rho(D) immune globulin,Dostarlimab,Certolizumab pegol,Inolimomab,Pentaglobin,Abagovomab,Efungumab,Foralumab,Indatuximab ravtansine,Magrolimab,Olinvacimab,Actoxumab,Volagidemab,Bentracimab,Amivantamab,Ebola Zaire vaccine (live, attenuated),Imdevimab,Casirivimab,Cilgavimab,Tixagevimab |
| Target | Glutamate carboxypeptidase 2 |
| Brand Name | ProstaScint Kit for the Preparation of Indium In 111 Capromab Pendetide |
| Company | Jazz Pharmaceuticals, Inc. |
| Brand Description | Jazz Pharmaceuticals, Inc. |
| Prescribed For | Intravenous |
| Chemical Name | 0.5 mg/1mL |
| Formulation | Indium In 111 ProstaScint® (capromab pendetide) should not be used in patients who are hypersensitive to this or any other product of murine origin or to Indium In 111 chloride. |
| Physical Appearance | ProstaScint® (capromab pendetide) was generally well tolerated in the clinical trials. After administration of 529 single doses of Indium In 111 ProstaScint®, adverse reactions were observed in 4% of patients. The most commonly reported adverse reactions were increases in bilirubin, hypotension, and hypertension, which occurred in 1% of patients. Elevated liver enzymes and injection site reactions occurred in slightly less than 1% of patients. Other adverse reactions, listed in order of decreasing frequency, were: pruritus, fever, rash, headache, myalgia, asthenia, burning sensation in thigh, shortness of breath, and alteration of taste. |
| Route of Administration | ProstaScint® (capromab pendetide) is the murine monoclonal antibody, 7E11-C5.3, conjugated to the linker-chelator, glycyl-tyrosyl-(N, ε-diethylenetriaminepentaacetic acid)-lysine hydrochloride (GYK-DTPA-HCl). The 7E11-C5.3 antibody is of the IgG1, kappa subclass (IgG1κ). This antibody is directed against a glycoprotein expressed by prostate epithelium known as Prostate Specific Membrane Antigen (PSMA). |
| Recommended Dosage | ProstaScint® (capromab pendetide) is indicated as a diagnostic imaging agent in newly-diagnosed patients with biopsy-proven prostate cancer, thought to be clinically-localized after standard diagnostic evaluation (e.g. chest x-ray, bone scan, CT scan, or MRI), who are at high-risk for pelvic lymph node metastases |
| Contraindication | [(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-4-hydroxy-2-(phosphonooxymethyl)oxolan-3-yl] dihydrogen phosphate |
| Side Effects | NA |
| Useful Link 1 | Link |
| Useful Link 2 | Link |
| Remarks | NA |
| Primary information | |
|---|---|
| ID | 11719 |
| Therapeutic ID | Th1254 |
| Protein Name | Capromab pendetide |
| Sequence | NA |
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting point | 61 °C (FAB fragment), 71 °C (whole mAb) |
| Half-life | NA |
| Description | Capromab is a Murine IgG1 monoclonal 7E11-C5.3 antibody that recognizes prostate specific membrane antigen (PSMA – also known as glutamate carboxypeptidase 2) from prostate cancer cells and normal prostate tissue. When linked to pendetide, capromab is used as a chelating agent for the radionuclide [Indium In-111] during imaging to evaluate the extent of prostate cancer. |
| Indication/Disease | For diagnosis of prostate cancer and detection of intra-pelvic metastases. |
| Pharmacodynamics | Binds to the prostate-specific membrane antigen, which is a cell surface protein generally overexpressed in prostate tissues and prostate cancers. The radioactive Indium 111, which is covalently attached to the antibody, allows radiodiagnostic detection of PSMA expressing cells and tumors. |
| Mechanism of Action | Binds selectively to cell-surface prostate-specific membrane antigen (PSMA) expressed on prostate tissues and tumors. |
| Toxicity | NA |
| Metabolism | Most likely removed by opsonization via the reticuloendothelial system or by human antimurine antibody production |
| Absorption | NA |
| * 4 ± 2.1 L | |
| Clearance | * 42 +/- 22 mL/hr |
| Categories | Antibodies |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | Glutamate carboxypeptidase 2 |
| Brand Name | NA |
| Company | NA |
| Brand Description | NA |
| Prescribed For | NA |
| Chemical Name | NA |
| Formulation | NA |
| Physical Appearance | NA |
| Route of Administration | NA |
| Recommended Dosage | NA |
| Contraindication | [(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-4-hydroxy-2-(phosphonooxymethyl)oxolan-3-yl] dihydrogen phosphate |
| Side Effects | NA |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |
| Primary information | |
|---|---|
| ID | 11720 |
| Therapeutic ID | Th1254 |
| Protein Name | Capromab pendetide |
| Sequence | NA |
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting point | 61 °C (FAB fragment), 71 °C (whole mAb) |
| Half-life | NA |
| Description | Capromab is a Murine IgG1 monoclonal 7E11-C5.3 antibody that recognizes prostate specific membrane antigen (PSMA – also known as glutamate carboxypeptidase 2) from prostate cancer cells and normal prostate tissue. When linked to pendetide, capromab is used as a chelating agent for the radionuclide [Indium In-111] during imaging to evaluate the extent of prostate cancer. |
| Indication/Disease | For diagnosis of prostate cancer and detection of intra-pelvic metastases. |
| Pharmacodynamics | Binds to the prostate-specific membrane antigen, which is a cell surface protein generally overexpressed in prostate tissues and prostate cancers. The radioactive Indium 111, which is covalently attached to the antibody, allows radiodiagnostic detection of PSMA expressing cells and tumors. |
| Mechanism of Action | Binds selectively to cell-surface prostate-specific membrane antigen (PSMA) expressed on prostate tissues and tumors. |
| Toxicity | NA |
| Metabolism | Most likely removed by opsonization via the reticuloendothelial system or by human antimurine antibody production |
| Absorption | NA |
| * 4 ± 2.1 L | |
| Clearance | * 42 +/- 22 mL/hr |
| Categories | Blood Proteins |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | Glutamate carboxypeptidase 2 |
| Brand Name | NA |
| Company | NA |
| Brand Description | NA |
| Prescribed For | NA |
| Chemical Name | NA |
| Formulation | NA |
| Physical Appearance | NA |
| Route of Administration | NA |
| Recommended Dosage | NA |
| Contraindication | [(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-4-hydroxy-2-(phosphonooxymethyl)oxolan-3-yl] dihydrogen phosphate |
| Side Effects | NA |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |
| Primary information | |
|---|---|
| ID | 11721 |
| Therapeutic ID | Th1254 |
| Protein Name | Capromab pendetide |
| Sequence | NA |
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting point | 61 °C (FAB fragment), 71 °C (whole mAb) |
| Half-life | NA |
| Description | Capromab is a Murine IgG1 monoclonal 7E11-C5.3 antibody that recognizes prostate specific membrane antigen (PSMA – also known as glutamate carboxypeptidase 2) from prostate cancer cells and normal prostate tissue. When linked to pendetide, capromab is used as a chelating agent for the radionuclide [Indium In-111] during imaging to evaluate the extent of prostate cancer. |
| Indication/Disease | For diagnosis of prostate cancer and detection of intra-pelvic metastases. |
| Pharmacodynamics | Binds to the prostate-specific membrane antigen, which is a cell surface protein generally overexpressed in prostate tissues and prostate cancers. The radioactive Indium 111, which is covalently attached to the antibody, allows radiodiagnostic detection of PSMA expressing cells and tumors. |
| Mechanism of Action | Binds selectively to cell-surface prostate-specific membrane antigen (PSMA) expressed on prostate tissues and tumors. |
| Toxicity | NA |
| Metabolism | Most likely removed by opsonization via the reticuloendothelial system or by human antimurine antibody production |
| Absorption | NA |
| * 4 ± 2.1 L | |
| Clearance | * 42 +/- 22 mL/hr |
| Categories | Compounds used in a research, industrial, or household setting |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | Glutamate carboxypeptidase 2 |
| Brand Name | NA |
| Company | NA |
| Brand Description | NA |
| Prescribed For | NA |
| Chemical Name | NA |
| Formulation | NA |
| Physical Appearance | NA |
| Route of Administration | NA |
| Recommended Dosage | NA |
| Contraindication | [(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-4-hydroxy-2-(phosphonooxymethyl)oxolan-3-yl] dihydrogen phosphate |
| Side Effects | NA |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |
| Primary information | |
|---|---|
| ID | 11722 |
| Therapeutic ID | Th1254 |
| Protein Name | Capromab pendetide |
| Sequence | NA |
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting point | 61 °C (FAB fragment), 71 °C (whole mAb) |
| Half-life | NA |
| Description | Capromab is a Murine IgG1 monoclonal 7E11-C5.3 antibody that recognizes prostate specific membrane antigen (PSMA – also known as glutamate carboxypeptidase 2) from prostate cancer cells and normal prostate tissue. When linked to pendetide, capromab is used as a chelating agent for the radionuclide [Indium In-111] during imaging to evaluate the extent of prostate cancer. |
| Indication/Disease | For diagnosis of prostate cancer and detection of intra-pelvic metastases. |
| Pharmacodynamics | Binds to the prostate-specific membrane antigen, which is a cell surface protein generally overexpressed in prostate tissues and prostate cancers. The radioactive Indium 111, which is covalently attached to the antibody, allows radiodiagnostic detection of PSMA expressing cells and tumors. |
| Mechanism of Action | Binds selectively to cell-surface prostate-specific membrane antigen (PSMA) expressed on prostate tissues and tumors. |
| Toxicity | NA |
| Metabolism | Most likely removed by opsonization via the reticuloendothelial system or by human antimurine antibody production |
| Absorption | NA |
| * 4 ± 2.1 L | |
| Clearance | * 42 +/- 22 mL/hr |
| Categories | Diagnostic Radiopharmaceuticals |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | Glutamate carboxypeptidase 2 |
| Brand Name | NA |
| Company | NA |
| Brand Description | NA |
| Prescribed For | NA |
| Chemical Name | NA |
| Formulation | NA |
| Physical Appearance | NA |
| Route of Administration | NA |
| Recommended Dosage | NA |
| Contraindication | [(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-4-hydroxy-2-(phosphonooxymethyl)oxolan-3-yl] dihydrogen phosphate |
| Side Effects | NA |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |
| Primary information | |
|---|---|
| ID | 11723 |
| Therapeutic ID | Th1254 |
| Protein Name | Capromab pendetide |
| Sequence | NA |
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting point | 61 °C (FAB fragment), 71 °C (whole mAb) |
| Half-life | NA |
| Description | Capromab is a Murine IgG1 monoclonal 7E11-C5.3 antibody that recognizes prostate specific membrane antigen (PSMA – also known as glutamate carboxypeptidase 2) from prostate cancer cells and normal prostate tissue. When linked to pendetide, capromab is used as a chelating agent for the radionuclide [Indium In-111] during imaging to evaluate the extent of prostate cancer. |
| Indication/Disease | For diagnosis of prostate cancer and detection of intra-pelvic metastases. |
| Pharmacodynamics | Binds to the prostate-specific membrane antigen, which is a cell surface protein generally overexpressed in prostate tissues and prostate cancers. The radioactive Indium 111, which is covalently attached to the antibody, allows radiodiagnostic detection of PSMA expressing cells and tumors. |
| Mechanism of Action | Binds selectively to cell-surface prostate-specific membrane antigen (PSMA) expressed on prostate tissues and tumors. |
| Toxicity | NA |
| Metabolism | Most likely removed by opsonization via the reticuloendothelial system or by human antimurine antibody production |
| Absorption | NA |
| * 4 ± 2.1 L | |
| Clearance | * 42 +/- 22 mL/hr |
| Categories | Globulins |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | Glutamate carboxypeptidase 2 |
| Brand Name | NA |
| Company | NA |
| Brand Description | NA |
| Prescribed For | NA |
| Chemical Name | NA |
| Formulation | NA |
| Physical Appearance | NA |
| Route of Administration | NA |
| Recommended Dosage | NA |
| Contraindication | [(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-4-hydroxy-2-(phosphonooxymethyl)oxolan-3-yl] dihydrogen phosphate |
| Side Effects | NA |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |
| Primary information | |
|---|---|
| ID | 11724 |
| Therapeutic ID | Th1254 |
| Protein Name | Capromab pendetide |
| Sequence | NA |
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting point | 61 °C (FAB fragment), 71 °C (whole mAb) |
| Half-life | NA |
| Description | Capromab is a Murine IgG1 monoclonal 7E11-C5.3 antibody that recognizes prostate specific membrane antigen (PSMA – also known as glutamate carboxypeptidase 2) from prostate cancer cells and normal prostate tissue. When linked to pendetide, capromab is used as a chelating agent for the radionuclide [Indium In-111] during imaging to evaluate the extent of prostate cancer. |
| Indication/Disease | For diagnosis of prostate cancer and detection of intra-pelvic metastases. |
| Pharmacodynamics | Binds to the prostate-specific membrane antigen, which is a cell surface protein generally overexpressed in prostate tissues and prostate cancers. The radioactive Indium 111, which is covalently attached to the antibody, allows radiodiagnostic detection of PSMA expressing cells and tumors. |
| Mechanism of Action | Binds selectively to cell-surface prostate-specific membrane antigen (PSMA) expressed on prostate tissues and tumors. |
| Toxicity | NA |
| Metabolism | Most likely removed by opsonization via the reticuloendothelial system or by human antimurine antibody production |
| Absorption | NA |
| * 4 ± 2.1 L | |
| Clearance | * 42 +/- 22 mL/hr |
| Categories | Immunoglobulins |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | Glutamate carboxypeptidase 2 |
| Brand Name | NA |
| Company | NA |
| Brand Description | NA |
| Prescribed For | NA |
| Chemical Name | NA |
| Formulation | NA |
| Physical Appearance | NA |
| Route of Administration | NA |
| Recommended Dosage | NA |
| Contraindication | [(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-4-hydroxy-2-(phosphonooxymethyl)oxolan-3-yl] dihydrogen phosphate |
| Side Effects | NA |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |
| Primary information | |
|---|---|
| ID | 11725 |
| Therapeutic ID | Th1254 |
| Protein Name | Capromab pendetide |
| Sequence | NA |
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting point | 61 °C (FAB fragment), 71 °C (whole mAb) |
| Half-life | NA |
| Description | Capromab is a Murine IgG1 monoclonal 7E11-C5.3 antibody that recognizes prostate specific membrane antigen (PSMA – also known as glutamate carboxypeptidase 2) from prostate cancer cells and normal prostate tissue. When linked to pendetide, capromab is used as a chelating agent for the radionuclide [Indium In-111] during imaging to evaluate the extent of prostate cancer. |
| Indication/Disease | For diagnosis of prostate cancer and detection of intra-pelvic metastases. |
| Pharmacodynamics | Binds to the prostate-specific membrane antigen, which is a cell surface protein generally overexpressed in prostate tissues and prostate cancers. The radioactive Indium 111, which is covalently attached to the antibody, allows radiodiagnostic detection of PSMA expressing cells and tumors. |
| Mechanism of Action | Binds selectively to cell-surface prostate-specific membrane antigen (PSMA) expressed on prostate tissues and tumors. |
| Toxicity | NA |
| Metabolism | Most likely removed by opsonization via the reticuloendothelial system or by human antimurine antibody production |
| Absorption | NA |
| * 4 ± 2.1 L | |
| Clearance | * 42 +/- 22 mL/hr |
| Categories | Immunoproteins |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | Glutamate carboxypeptidase 2 |
| Brand Name | NA |
| Company | NA |
| Brand Description | NA |
| Prescribed For | NA |
| Chemical Name | NA |
| Formulation | NA |
| Physical Appearance | NA |
| Route of Administration | NA |
| Recommended Dosage | NA |
| Contraindication | [(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-4-hydroxy-2-(phosphonooxymethyl)oxolan-3-yl] dihydrogen phosphate |
| Side Effects | NA |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |
| Primary information | |
|---|---|
| ID | 11726 |
| Therapeutic ID | Th1254 |
| Protein Name | Capromab pendetide |
| Sequence | NA |
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting point | 61 °C (FAB fragment), 71 °C (whole mAb) |
| Half-life | NA |
| Description | Capromab is a Murine IgG1 monoclonal 7E11-C5.3 antibody that recognizes prostate specific membrane antigen (PSMA – also known as glutamate carboxypeptidase 2) from prostate cancer cells and normal prostate tissue. When linked to pendetide, capromab is used as a chelating agent for the radionuclide [Indium In-111] during imaging to evaluate the extent of prostate cancer. |
| Indication/Disease | For diagnosis of prostate cancer and detection of intra-pelvic metastases. |
| Pharmacodynamics | Binds to the prostate-specific membrane antigen, which is a cell surface protein generally overexpressed in prostate tissues and prostate cancers. The radioactive Indium 111, which is covalently attached to the antibody, allows radiodiagnostic detection of PSMA expressing cells and tumors. |
| Mechanism of Action | Binds selectively to cell-surface prostate-specific membrane antigen (PSMA) expressed on prostate tissues and tumors. |
| Toxicity | NA |
| Metabolism | Most likely removed by opsonization via the reticuloendothelial system or by human antimurine antibody production |
| Absorption | NA |
| * 4 ± 2.1 L | |
| Clearance | * 42 +/- 22 mL/hr |
| Categories | Indicators and Reagents |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | Glutamate carboxypeptidase 2 |
| Brand Name | NA |
| Company | NA |
| Brand Description | NA |
| Prescribed For | NA |
| Chemical Name | NA |
| Formulation | NA |
| Physical Appearance | NA |
| Route of Administration | NA |
| Recommended Dosage | NA |
| Contraindication | [(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-4-hydroxy-2-(phosphonooxymethyl)oxolan-3-yl] dihydrogen phosphate |
| Side Effects | NA |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |
| Primary information | |
|---|---|
| ID | 11727 |
| Therapeutic ID | Th1254 |
| Protein Name | Capromab pendetide |
| Sequence | NA |
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting point | 61 °C (FAB fragment), 71 °C (whole mAb) |
| Half-life | NA |
| Description | Capromab is a Murine IgG1 monoclonal 7E11-C5.3 antibody that recognizes prostate specific membrane antigen (PSMA – also known as glutamate carboxypeptidase 2) from prostate cancer cells and normal prostate tissue. When linked to pendetide, capromab is used as a chelating agent for the radionuclide [Indium In-111] during imaging to evaluate the extent of prostate cancer. |
| Indication/Disease | For diagnosis of prostate cancer and detection of intra-pelvic metastases. |
| Pharmacodynamics | Binds to the prostate-specific membrane antigen, which is a cell surface protein generally overexpressed in prostate tissues and prostate cancers. The radioactive Indium 111, which is covalently attached to the antibody, allows radiodiagnostic detection of PSMA expressing cells and tumors. |
| Mechanism of Action | Binds selectively to cell-surface prostate-specific membrane antigen (PSMA) expressed on prostate tissues and tumors. |
| Toxicity | NA |
| Metabolism | Most likely removed by opsonization via the reticuloendothelial system or by human antimurine antibody production |
| Absorption | NA |
| * 4 ± 2.1 L | |
| Clearance | * 42 +/- 22 mL/hr |
| Categories | Indium (111In) Compounds |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | Glutamate carboxypeptidase 2 |
| Brand Name | NA |
| Company | NA |
| Brand Description | NA |
| Prescribed For | NA |
| Chemical Name | NA |
| Formulation | NA |
| Physical Appearance | NA |
| Route of Administration | NA |
| Recommended Dosage | NA |
| Contraindication | [(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-4-hydroxy-2-(phosphonooxymethyl)oxolan-3-yl] dihydrogen phosphate |
| Side Effects | NA |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |
| Primary information | |
|---|---|
| ID | 11728 |
| Therapeutic ID | Th1254 |
| Protein Name | Capromab pendetide |
| Sequence | NA |
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting point | 61 °C (FAB fragment), 71 °C (whole mAb) |
| Half-life | NA |
| Description | Capromab is a Murine IgG1 monoclonal 7E11-C5.3 antibody that recognizes prostate specific membrane antigen (PSMA – also known as glutamate carboxypeptidase 2) from prostate cancer cells and normal prostate tissue. When linked to pendetide, capromab is used as a chelating agent for the radionuclide [Indium In-111] during imaging to evaluate the extent of prostate cancer. |
| Indication/Disease | For diagnosis of prostate cancer and detection of intra-pelvic metastases. |
| Pharmacodynamics | Binds to the prostate-specific membrane antigen, which is a cell surface protein generally overexpressed in prostate tissues and prostate cancers. The radioactive Indium 111, which is covalently attached to the antibody, allows radiodiagnostic detection of PSMA expressing cells and tumors. |
| Mechanism of Action | Binds selectively to cell-surface prostate-specific membrane antigen (PSMA) expressed on prostate tissues and tumors. |
| Toxicity | NA |
| Metabolism | Most likely removed by opsonization via the reticuloendothelial system or by human antimurine antibody production |
| Absorption | NA |
| * 4 ± 2.1 L | |
| Clearance | * 42 +/- 22 mL/hr |
| Categories | Indium Radioisotopes |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | Glutamate carboxypeptidase 2 |
| Brand Name | NA |
| Company | NA |
| Brand Description | NA |
| Prescribed For | NA |
| Chemical Name | NA |
| Formulation | NA |
| Physical Appearance | NA |
| Route of Administration | NA |
| Recommended Dosage | NA |
| Contraindication | [(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-4-hydroxy-2-(phosphonooxymethyl)oxolan-3-yl] dihydrogen phosphate |
| Side Effects | NA |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |
| Primary information | |
|---|---|
| ID | 11729 |
| Therapeutic ID | Th1254 |
| Protein Name | Capromab pendetide |
| Sequence | NA |
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting point | 61 °C (FAB fragment), 71 °C (whole mAb) |
| Half-life | NA |
| Description | Capromab is a Murine IgG1 monoclonal 7E11-C5.3 antibody that recognizes prostate specific membrane antigen (PSMA – also known as glutamate carboxypeptidase 2) from prostate cancer cells and normal prostate tissue. When linked to pendetide, capromab is used as a chelating agent for the radionuclide [Indium In-111] during imaging to evaluate the extent of prostate cancer. |
| Indication/Disease | For diagnosis of prostate cancer and detection of intra-pelvic metastases. |
| Pharmacodynamics | Binds to the prostate-specific membrane antigen, which is a cell surface protein generally overexpressed in prostate tissues and prostate cancers. The radioactive Indium 111, which is covalently attached to the antibody, allows radiodiagnostic detection of PSMA expressing cells and tumors. |
| Mechanism of Action | Binds selectively to cell-surface prostate-specific membrane antigen (PSMA) expressed on prostate tissues and tumors. |
| Toxicity | NA |
| Metabolism | Most likely removed by opsonization via the reticuloendothelial system or by human antimurine antibody production |
| Absorption | NA |
| * 4 ± 2.1 L | |
| Clearance | * 42 +/- 22 mL/hr |
| Categories | Laboratory Chemicals |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | Glutamate carboxypeptidase 2 |
| Brand Name | NA |
| Company | NA |
| Brand Description | NA |
| Prescribed For | NA |
| Chemical Name | NA |
| Formulation | NA |
| Physical Appearance | NA |
| Route of Administration | NA |
| Recommended Dosage | NA |
| Contraindication | [(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-4-hydroxy-2-(phosphonooxymethyl)oxolan-3-yl] dihydrogen phosphate |
| Side Effects | NA |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |
| Primary information | |
|---|---|
| ID | 11730 |
| Therapeutic ID | Th1254 |
| Protein Name | Capromab pendetide |
| Sequence | NA |
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting point | 61 °C (FAB fragment), 71 °C (whole mAb) |
| Half-life | NA |
| Description | Capromab is a Murine IgG1 monoclonal 7E11-C5.3 antibody that recognizes prostate specific membrane antigen (PSMA – also known as glutamate carboxypeptidase 2) from prostate cancer cells and normal prostate tissue. When linked to pendetide, capromab is used as a chelating agent for the radionuclide [Indium In-111] during imaging to evaluate the extent of prostate cancer. |
| Indication/Disease | For diagnosis of prostate cancer and detection of intra-pelvic metastases. |
| Pharmacodynamics | Binds to the prostate-specific membrane antigen, which is a cell surface protein generally overexpressed in prostate tissues and prostate cancers. The radioactive Indium 111, which is covalently attached to the antibody, allows radiodiagnostic detection of PSMA expressing cells and tumors. |
| Mechanism of Action | Binds selectively to cell-surface prostate-specific membrane antigen (PSMA) expressed on prostate tissues and tumors. |
| Toxicity | NA |
| Metabolism | Most likely removed by opsonization via the reticuloendothelial system or by human antimurine antibody production |
| Absorption | NA |
| * 4 ± 2.1 L | |
| Clearance | * 42 +/- 22 mL/hr |
| Categories | Prostatic Neoplasms |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | Glutamate carboxypeptidase 2 |
| Brand Name | NA |
| Company | NA |
| Brand Description | NA |
| Prescribed For | NA |
| Chemical Name | NA |
| Formulation | NA |
| Physical Appearance | NA |
| Route of Administration | NA |
| Recommended Dosage | NA |
| Contraindication | [(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-4-hydroxy-2-(phosphonooxymethyl)oxolan-3-yl] dihydrogen phosphate |
| Side Effects | NA |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |
| Primary information | |
|---|---|
| ID | 11731 |
| Therapeutic ID | Th1254 |
| Protein Name | Capromab pendetide |
| Sequence | NA |
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting point | 61 °C (FAB fragment), 71 °C (whole mAb) |
| Half-life | NA |
| Description | Capromab is a Murine IgG1 monoclonal 7E11-C5.3 antibody that recognizes prostate specific membrane antigen (PSMA – also known as glutamate carboxypeptidase 2) from prostate cancer cells and normal prostate tissue. When linked to pendetide, capromab is used as a chelating agent for the radionuclide [Indium In-111] during imaging to evaluate the extent of prostate cancer. |
| Indication/Disease | For diagnosis of prostate cancer and detection of intra-pelvic metastases. |
| Pharmacodynamics | Binds to the prostate-specific membrane antigen, which is a cell surface protein generally overexpressed in prostate tissues and prostate cancers. The radioactive Indium 111, which is covalently attached to the antibody, allows radiodiagnostic detection of PSMA expressing cells and tumors. |
| Mechanism of Action | Binds selectively to cell-surface prostate-specific membrane antigen (PSMA) expressed on prostate tissues and tumors. |
| Toxicity | NA |
| Metabolism | Most likely removed by opsonization via the reticuloendothelial system or by human antimurine antibody production |
| Absorption | NA |
| * 4 ± 2.1 L | |
| Clearance | * 42 +/- 22 mL/hr |
| Categories | Proteins |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | Glutamate carboxypeptidase 2 |
| Brand Name | NA |
| Company | NA |
| Brand Description | NA |
| Prescribed For | NA |
| Chemical Name | NA |
| Formulation | NA |
| Physical Appearance | NA |
| Route of Administration | NA |
| Recommended Dosage | NA |
| Contraindication | [(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-4-hydroxy-2-(phosphonooxymethyl)oxolan-3-yl] dihydrogen phosphate |
| Side Effects | NA |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |
| Primary information | |
|---|---|
| ID | 11732 |
| Therapeutic ID | Th1254 |
| Protein Name | Capromab pendetide |
| Sequence | NA |
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting point | 61 °C (FAB fragment), 71 °C (whole mAb) |
| Half-life | NA |
| Description | Capromab is a Murine IgG1 monoclonal 7E11-C5.3 antibody that recognizes prostate specific membrane antigen (PSMA – also known as glutamate carboxypeptidase 2) from prostate cancer cells and normal prostate tissue. When linked to pendetide, capromab is used as a chelating agent for the radionuclide [Indium In-111] during imaging to evaluate the extent of prostate cancer. |
| Indication/Disease | For diagnosis of prostate cancer and detection of intra-pelvic metastases. |
| Pharmacodynamics | Binds to the prostate-specific membrane antigen, which is a cell surface protein generally overexpressed in prostate tissues and prostate cancers. The radioactive Indium 111, which is covalently attached to the antibody, allows radiodiagnostic detection of PSMA expressing cells and tumors. |
| Mechanism of Action | Binds selectively to cell-surface prostate-specific membrane antigen (PSMA) expressed on prostate tissues and tumors. |
| Toxicity | NA |
| Metabolism | Most likely removed by opsonization via the reticuloendothelial system or by human antimurine antibody production |
| Absorption | NA |
| * 4 ± 2.1 L | |
| Clearance | * 42 +/- 22 mL/hr |
| Categories | Serum Globulins |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | Glutamate carboxypeptidase 2 |
| Brand Name | NA |
| Company | NA |
| Brand Description | NA |
| Prescribed For | NA |
| Chemical Name | NA |
| Formulation | NA |
| Physical Appearance | NA |
| Route of Administration | NA |
| Recommended Dosage | NA |
| Contraindication | [(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-4-hydroxy-2-(phosphonooxymethyl)oxolan-3-yl] dihydrogen phosphate |
| Side Effects | NA |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |
| Primary information | |
|---|---|
| ID | 11733 |
| Therapeutic ID | Th1254 |
| Protein Name | Capromab pendetide |
| Sequence | NA |
| Molecular Weight | NA |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting point | 61 °C (FAB fragment), 71 °C (whole mAb) |
| Half-life | NA |
| Description | Capromab is a Murine IgG1 monoclonal 7E11-C5.3 antibody that recognizes prostate specific membrane antigen (PSMA – also known as glutamate carboxypeptidase 2) from prostate cancer cells and normal prostate tissue. When linked to pendetide, capromab is used as a chelating agent for the radionuclide [Indium In-111] during imaging to evaluate the extent of prostate cancer. |
| Indication/Disease | For diagnosis of prostate cancer and detection of intra-pelvic metastases. |
| Pharmacodynamics | Binds to the prostate-specific membrane antigen, which is a cell surface protein generally overexpressed in prostate tissues and prostate cancers. The radioactive Indium 111, which is covalently attached to the antibody, allows radiodiagnostic detection of PSMA expressing cells and tumors. |
| Mechanism of Action | Binds selectively to cell-surface prostate-specific membrane antigen (PSMA) expressed on prostate tissues and tumors. |
| Toxicity | NA |
| Metabolism | Most likely removed by opsonization via the reticuloendothelial system or by human antimurine antibody production |
| Absorption | NA |
| * 4 ± 2.1 L | |
| Clearance | * 42 +/- 22 mL/hr |
| Categories | Tumour Detection |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | Glutamate carboxypeptidase 2 |
| Brand Name | NA |
| Company | NA |
| Brand Description | NA |
| Prescribed For | NA |
| Chemical Name | NA |
| Formulation | NA |
| Physical Appearance | NA |
| Route of Administration | NA |
| Recommended Dosage | NA |
| Contraindication | [(2R,3S,4R,5R)-5-(2-amino-6-oxo-1H-purin-9-yl)-4-hydroxy-2-(phosphonooxymethyl)oxolan-3-yl] dihydrogen phosphate |
| Side Effects | NA |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |